Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls
NCT07555132 · OxySPECTRUM · University Hospital, Basel, Switzerland
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Change in area under the concentration time curve in plasma neurophysin I
Measured over From baseline (before intake) to 5 hours after a single dose administration of MDMA or placebo
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| University Hospital Basel, Endocrinology, Diabetes and Metabolism | Basel | — | Switzerland |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT07555132 on ClinicalTrials.gov →
Last updated in the registry 2026-04-29. Registry records change; this page reflects the data build of 2026-08-25.
Related